Expanding the reach of highly potent cancer therapies with the pre|CISION® platform.
United Kingdom
Joined January 2014
- Tweets1.9K
- Following172
- Followers8.7K
- Likes65
Avacta retweeted
Join AVACTA GROUP PLC's Phase 1b Faridoxorubicin (AVA6000) Salivary Gland Cancer Data Release TOMORROW at 10:00am - Click below to register. #AVCT @avacta
investormeetcompany.com/avac…
Avacta retweeted
Delighted to share a great conversation about #AVCT with Tom Weir on the Biohub podcast Ep 97. An exciting time for Avacta is on the horizon!
#HopeWithoutCompromise
linkedin.com/posts/christina…
Avacta retweeted
#LondonLifeSciences Week. Avacta Tx thrilled to be selected as the Company to Watch using AI as an accelerator in drug development. So proud of our team and everything we have accomplished.
#AVCT
#HopeWithoutCompromise
linkedin.com/posts/christina…
Avacta retweeted
Join AVACTA GROUP PLC's Investor Presentation on 29th Oct 2025 at 4:00pm GMT, Click below to register. #AVCT @avacta
investormeetcompany.com/avac…
Avacta retweeted
Thrilled to be at #ESMO25 for the Faridox Ph Ia presentation. Moving at the speed of light here! Poster session was jammed and our own #AVCT AVA6K had quite a day.
#LetsDoThis
#CancerGoingDown
#preCISEDelivery
#HopeWithoutCompromise
Avacta Therapeutics presents compelling Phase 1a data for faridoxorubicin and the pre|CISION platform at the European Society of Medical Oncology Annual Congress. avacta.com/avacta-therapeuti… #AVCT #ESMO25
Avacta retweeted
#AVCT updated website rolling out with the homepage. Gives a flavor for what our technology can do
#HopeWithoutCompromise
Avacta retweeted
New CB terms show @avacta confidence in securing funds to advance #preCISION assets thru clinical dev, supported by key #AVA6000 data in 25/26. 2nd equity raise to settle qtrly CB repayments w/ less dilution. For more on #AVCT trinitydelta.org/companies/a…
Avacta retweeted
New IP & Tempus AI collaboration cld support @avacta's product & tech-based business dev. #preCISION pipeline progressing w #AVA6000 Ph I SGC data in H225 & TNBC in H126, & #AVA6103 IND enabling ongoing ahead of 2026 Ph I start. For more on #AVCT: trinitydelta.org/companies/a…
Avacta retweeted
Delighted to be at #BiotechWeekBoston connecting with industry and highlighting the great progress preCISION continues to make in clinic. #AVCT @avacta
#LetsDoThis
#PeptidesCreateHope
#HopeWithoutCompromise
Avacta retweeted
Key 25/26 data from @avacta's lead #preCISION progs: 1) #AVA6000 (FAP-Dox) initial #SGC data late-25 & #TNBC data H126; subject to funding, Phase II in both planned for H126. 2) AVA6103 (FAP-EXd) IND sub late-25, Phase I start Q126 & 1st data Q426 #AVCT trinitydelta.org/companies/a…
Avacta retweeted
Couldn't make today's live presentation with AVACTA GROUP PLC? #AVCT @avacta
No problem! Catch up here: youtube.com/watch?v=ajabya7W…
Avacta retweeted
Strategic delivery at @avacta as Dx disposal extends cash into Q126 + pre|CISION assets progress: #AVA6000 (enrolling SGS & TNBC Ph Ib expansion cohorts) & #AVA6103 (candidate selected Ph I start early-26). Multiple '25-26 value inflection points #AVCT trinitydelta.org/companies/a…
Avacta retweeted
Our @avacta Outlook reviews the science & opportunity behind pre|CISION & a PDC pipeline designed to target highly potent drugs to the TME expanding their reach & limiting systemic tox. Pipeline progress & Dx divestment are value-inflection points #AVCT trinitydelta.org/companies/a…
Avacta retweeted
Preclin data highlight potential of @avacta's pre|CISION tech & pipeline beyond AVA6000 w AVA6103 (#exatecan PDC) & AVA7100 (1st #AffDC). Delivery of highly potent payloads to TME (red systemic tox/imp Tx index) + potential to treat low FAP tumours. #AVCT trinitydelta.org/companies/a…
Avacta retweeted
The evolution of preCISION is being unveiled today in Barcelona. We believe the future of cancer therapy means not having to choose between eliminating the disease and safeguarding patient wellness. We believe in hope without compromise.
#PeptidesCreateHope
#LetsDoThis
#AVCT
Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona. avacta.com/avacta-reports-pi… #AVCT
Avacta retweeted
Oct 30 R&D event shld cover @avacta's pipeline plans as it transitions into a pure-play novel highly-targeted #cancer drug developer enabled by its pre|CISION platform. H124 results confirm £32.5m cash, Dx divestment plan & potential for dual NASDAQ list. trinitydelta.org/companies/a…
Avacta retweeted
Couldn't make today's live presentation with AVACTA GROUP PLC? #AVCT avacta
No problem! Catch up here: youtube.com/watch?v=IROUElHy…
Avacta retweeted
Join AVACTA GROUP PLC's Investor Presentation on 30th Sep 2024 at 11:00am BST, Click below to register. #AVCT avacta
investormeetcompany.com/avac…
Avacta retweeted
We are delighted to report the significant progress on multiple fronts from the AVA6000 team @avacta
Bringing powerful new tools to this trial to better characterize responses and indications
#LetsDoThis
#PeptidesCreateHope
Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta’s AVA6000 Phase 1 trial. avacta.com/successful-comple… #AVCT @sofiebio
Avacta retweeted
I am thrilled to take this new role at Avacta and lead us into the next chapter
#LetsDoThis
#PeptidesCreateHope
Avacta announces that Christina Coughlin, MD, PhD, has been appointed as the new Chief Executive Officer of Avacta. avacta.com/christina-coughli… #AVCT
